Positive News SentimentPositive NewsNASDAQ:PLSE Pulse Biosciences (PLSE) Stock Forecast, Price & News $5.97 -0.15 (-2.45%) (As of 05/30/2023 ET) Add Compare Share Share Today's Range$5.86▼$6.2750-Day Range$2.48▼$8.6452-Week Range$1.18▼$9.69Volume70,074 shsAverage Volume88,775 shsMarket Capitalization$224.71 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Pulse Biosciences MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestBearish28.14% of Float Sold ShortDividend StrengthN/ASustainability-0.60Upright™ Environmental ScoreNews SentimentN/AInsider TradingAcquiring Shares$65.25 M Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.83 out of 5 starsMedical Sector834th out of 1,009 stocksSurgical & Medical Instruments Industry84th out of 104 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Pulse Biosciences. Previous Next 2.0 Short Interest Percentage of Shares Shorted28.14% of the float of Pulse Biosciences has been sold short.Short Interest Ratio / Days to CoverPulse Biosciences has a short interest ratio ("days to cover") of 16.3, which indicates bearish sentiment.Change versus previous monthShort interest in Pulse Biosciences has recently decreased by 6.15%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldPulse Biosciences does not currently pay a dividend.Dividend GrowthPulse Biosciences does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScorePulse Biosciences has received a 61.90% net impact score from Upright. Pulse Biosciences seems to create the most significant positive value in categories "Jobs", "Physical diseases", and "Taxes". The positive contribution in the "Physical diseases" impact category is mostly driven by its "Diagnostic and treatment machines", "Medical devices engineering", and "Clinical research services for cancer" products. See details.Environmental SustainabilityThe Environmental Impact score for Pulse Biosciences is -0.60. Previous Next 3.3 News and Social Media Coverage News SentimentPulse Biosciences has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Pulse Biosciences this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for PLSE on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat Follows4 people have added Pulse Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Pulse Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $65,249,320.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders55.00% of the stock of Pulse Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 6.56% of the stock of Pulse Biosciences is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Pulse Biosciences is -4.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pulse Biosciences is -4.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Pulse Biosciences (NASDAQ:PLSE) StockPulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments uses a novel and proprietary platform technology called Nano-Pulse Electro-Signaling. The NPES provides local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the cells. The company was founded on May 19, 2014 and is headquartered in Hayward, CA.Read More Receive PLSE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pulse Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address PLSE Stock News HeadlinesMay 22, 2023 | americanbankingnews.comPulse Biosciences (NASDAQ:PLSE) Coverage Initiated at StockNews.comMay 18, 2023 | finance.yahoo.comPulse Biosciences’ Nanosecond Pulsed Field Ablation (nsPFA™) Technology to be Featured in Several Presentations at The Heart Rhythm 2023 Annual MeetingMay 30, 2023 | Legacy Research (Affiliate) (Ad)The “Amazon Secret Royalty Program” Can Help Anyone Retire Like RoyaltyA unique type of investment could help you make more money than you will need for the rest of your life. It’s what we call the “Amazon secret royalty program.” It’s an income stream that allows you to collect $1,000s… $10,000s… or more every year! Learn how to collect your first payout before June 13th.May 17, 2023 | markets.businessinsider.comMaxim Group Sticks to Their Hold Rating for Pulse Biosciences (PLSE)May 16, 2023 | finance.yahoo.comPulse Biosciences, Inc. (NASDAQ:PLSE) Q1 2023 Earnings Call TranscriptMay 12, 2023 | finance.yahoo.comQ1 2023 Pulse Biosciences Inc Earnings CallMay 11, 2023 | msn.comRecap: Pulse Biosciences Q1 EarningsMay 11, 2023 | finance.yahoo.comPulse Biosciences Reports Business Updates and First Quarter 2023 Financial ResultsMay 30, 2023 | MarketBeat Internal (Ad)Introducing MarketBeat All AccessGet real-time financial news and market data with MarketBeat All Access. Monitor your portfolio and the markets. Access our top stock picks, unbeatable research tools, best-in-class stock screeners, and proprietary research reports.May 11, 2023 | americanbankingnews.comPulse Biosciences, Inc. (NASDAQ:PLSE) Director Robert W. Duggan Purchases 10,022,937 Shares of StockMay 10, 2023 | msn.comPulse Biosciences to notify planned redemption of warrantsMay 10, 2023 | finance.yahoo.comPulse Biosciences, Inc. Announces Planned Redemption of WarrantsMay 9, 2023 | americanbankingnews.comPulse Biosciences (PLSE) to Release Earnings on ThursdayMay 6, 2023 | marketwatch.com8-K: Pulse Biosciences, Inc.May 5, 2023 | benzinga.comPulse Biosciences Chief Executive Officer Awarded $3.73M Worth of Stock OptionsMay 3, 2023 | finance.yahoo.comPulse Biosciences, Inc. Appoints Dr. Gan Dunnington as Chief Medical OfficerMay 1, 2023 | finance.yahoo.comPulse Biosciences Announces $65 Million Private PlacementApril 27, 2023 | finance.yahoo.comPulse Biosciences Schedules First Quarter 2023 Financial Results Conference Call for May 11, 2023April 21, 2023 | americanbankingnews.comAnalyzing Pulse Biosciences (NASDAQ:PLSE) and Paragon 28 (NYSE:FNA)April 20, 2023 | finance.yahoo.comAs Pulse Biosciences, Inc. (NASDAQ:PLSE) hits US$217m market cap, insiders may be dismayed about not purchasing higher quantitiesApril 6, 2023 | americanbankingnews.comFinancial Analysis: Pulse Biosciences (NASDAQ:PLSE) & Apollo Endosurgery (NASDAQ:APEN)April 6, 2023 | americanbankingnews.comPulse Biosciences (NASDAQ:PLSE) Rating Increased to Sell at StockNews.comApril 5, 2023 | finance.yahoo.comPulse Biosciences, Inc. (NASDAQ:PLSE) Q4 2022 Earnings Call TranscriptApril 1, 2023 | americanbankingnews.comPulse Biosciences (NASDAQ:PLSE) Posts Earnings ResultsMarch 30, 2023 | finance.yahoo.comPulse Biosciences Reports Fourth Quarter & Full Year 2022 Financial ResultsMarch 29, 2023 | markets.businessinsider.comPulse Biosciences is about to announce its earnings — here's what Wall Street expectsMarch 29, 2023 | msn.comA Preview Of Pulse Biosciences's EarningsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive PLSE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pulse Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address PLSE Company Calendar Last Earnings5/11/2023Today5/30/2023Next Earnings (Estimated)8/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PLSE CUSIPN/A CIK1625101 Webwww.pulsebiosciences.com Phone(510) 906-4600FaxN/AEmployees142Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.44) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-58,510,000.00 Net MarginsN/A Pretax Margin-19,934.77% Return on Equity-1,185.19% Return on Assets-71.59% Debt Debt-to-Equity Ratio10.50 Current Ratio7.86 Quick Ratio7.86 Sales & Book Value Annual Sales$700,000.00 Price / Sales321.02 Cash FlowN/A Price / Cash FlowN/A Book Value($0.06) per share Price / Book-99.50Miscellaneous Outstanding Shares37,640,000Free Float16,939,000Market Cap$224.71 million OptionableOptionable Beta1.13 Key ExecutivesKevin P. DanahyPresident, Chief Executive & Financial OfficerEdison ManuelVice President-OperationsDarrin R. UeckerDirector & Chief Technology OfficerDavid DanitzSenior Vice President-EngineeringDunnington GansevoortChief Medical OfficerKey CompetitorsQuipt Home MedicalNASDAQ:QIPTTELA BioNASDAQ:TELASurmodicsNASDAQ:SRDXAlpha Tau MedicalNASDAQ:DRTSApyx MedicalNASDAQ:APYXView All CompetitorsInsiders & InstitutionsWestside Investment Management Inc.Sold 27,508 shares on 5/17/2023Ownership: 0.295%Geode Capital Management LLCBought 2,933 shares on 5/16/2023Ownership: 0.379%Spotlight Asset Group Inc.Bought 66,425 shares on 5/16/2023Ownership: 0.176%Bank of America Corp DEBought 3,994 shares on 5/12/2023Ownership: 2.056%Robert W DugganBought 10,022,937 shares on 5/9/2023Total: $65.25 M ($6.51/share)View All Insider TransactionsView All Institutional Transactions PLSE Stock - Frequently Asked Questions Should I buy or sell Pulse Biosciences stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pulse Biosciences in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PLSE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PLSE, but not buy additional shares or sell existing shares. View PLSE analyst ratings or view top-rated stocks. How have PLSE shares performed in 2023? Pulse Biosciences' stock was trading at $2.77 at the beginning of the year. Since then, PLSE shares have increased by 115.5% and is now trading at $5.97. View the best growth stocks for 2023 here. When is Pulse Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023. View our PLSE earnings forecast. How were Pulse Biosciences' earnings last quarter? Pulse Biosciences, Inc. (NASDAQ:PLSE) released its quarterly earnings data on Thursday, May, 11th. The company reported ($0.25) earnings per share for the quarter. What is Darrin R. Uecker's approval rating as Pulse Biosciences' CEO? 2 employees have rated Pulse Biosciences Chief Executive Officer Darrin R. Uecker on Glassdoor.com. Darrin R. Uecker has an approval rating of 100% among the company's employees. This puts Darrin R. Uecker in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Pulse Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pulse Biosciences investors own include Advanced Micro Devices (AMD), AbbVie (ABBV), Bausch Health Companies (BHC), Wayfair (W), Achaogen (AKAO), NVIDIA (NVDA), Portola Pharmaceuticals (PTLA), Enphase Energy (ENPH) and Novavax (NVAX). When did Pulse Biosciences IPO? (PLSE) raised $20 million in an IPO on Wednesday, May 18th 2016. The company issued 5,000,000 shares at a price of $4.00 per share. MDB Capital Group and Feltl and Company served as the underwriters for the IPO. What is Pulse Biosciences' stock symbol? Pulse Biosciences trades on the NASDAQ under the ticker symbol "PLSE." Who are Pulse Biosciences' major shareholders? Pulse Biosciences' stock is owned by many different institutional and retail investors. Top institutional investors include Bank of America Corp DE (2.06%), Griffin Asset Management Inc. (0.45%), Geode Capital Management LLC (0.38%), Westside Investment Management Inc. (0.30%), Spotlight Asset Group Inc. (0.18%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Kevin Patrick Danahy, Maky Zanganeh, Mitchell E Levinson and Robert W Duggan. View institutional ownership trends. How do I buy shares of Pulse Biosciences? Shares of PLSE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Pulse Biosciences' stock price today? One share of PLSE stock can currently be purchased for approximately $5.97. How much money does Pulse Biosciences make? Pulse Biosciences (NASDAQ:PLSE) has a market capitalization of $224.71 million and generates $700,000.00 in revenue each year. The company earns $-58,510,000.00 in net income (profit) each year or ($1.44) on an earnings per share basis. How many employees does Pulse Biosciences have? The company employs 142 workers across the globe. How can I contact Pulse Biosciences? Pulse Biosciences' mailing address is 3957 POINT EDEN WAY, HAYWARD CA, 94545. The official website for the company is www.pulsebiosciences.com. The company can be reached via phone at (510) 906-4600 or via email at ir@pulsebiosciences.com. This page (NASDAQ:PLSE) was last updated on 5/30/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pulse Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.